Advertisement

U.S. markets closed

S&P 500
4,274.04
-31.16(-0.72%)
Dow 30
33,980.32
-171.69(-0.50%)
Nasdaq
12,938.12
-164.43(-1.25%)
Russell 2000
1,987.31
-33.22(-1.64%)
Crude Oil
87.29
-0.82(-0.93%)
Gold
1,776.30
-0.40(-0.02%)

Advertisement

TG Therapeutics, Inc. (TGTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

7.43

-0.35

(-4.50%)

At close: 04:00PM EDT

7.59

+0.16

(+2.15%)

After hours:

05:41PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Engulfing Line (Bearish)

View all chart patterns

Performance Outlook

Previous Close	7.78
Open	7.60
Bid	7.37 x 800
Ask	7.58 x 1400
Day's Range	7.36 - 7.82
52 Week Range	3.48 - 35.94
Volume	1,946,692
Avg. Volume	3,356,703

Market Cap	1.079B
Beta (5Y Monthly)	2.27
PE Ratio (TTM)	N/A
EPS (TTM)	-2.46
Earnings Date	Nov 02, 2022 - Nov 07, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	16.88

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TGTX

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

TG Therapeutics, Inc.
Analyst Report: Vertex Pharmaceuticals, Inc.Vertex Pharmaceuticals develops therapies to address cystic fibrosis and other diseases. The company was founded in 1989 in Cambridge, Massachusetts and has 3,500 employees. It has research programs and facilities in the U.S., the U.K., and Canada. The shares are a component of the S&P 500.
Rating
Fair Value
Economic Moat
5 days agoArgus Research

All

Zacks
Can TG Therapeutics (TGTX) Climb 193% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for TG Therapeutics (TGTX) points to a 192.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Simply Wall St.
TG Therapeutics (NASDAQ:TGTX) adds US$271m to market cap in the past 7 days, though investors from a year ago are still down 64%
This month, we saw the TG Therapeutics, Inc. ( NASDAQ:TGTX ) up an impressive 53%. But that doesn't change the fact...
Zacks
TG Therapeutics (TGTX) Reports Q2 Loss, Tops Revenue Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 38.78% and 590.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Advertisement

S&P 5004,274.04-31.16(-0.72%)

Dow 3033,980.32-171.69(-0.50%)

Nasdaq12,938.12-164.43(-1.25%)

Russell 20001,987.31-33.22(-1.64%)

Crude Oil87.29-0.82(-0.93%)

Gold1,776.30-0.40(-0.02%)

TG Therapeutics, Inc. (TGTX)

Chart Events

Performance Outlook

Fair Value

Related Research

Can TG Therapeutics (TGTX) Climb 193% to Reach the Level Wall Street Analysts Expect?

TG Therapeutics (NASDAQ:TGTX) adds US$271m to market cap in the past 7 days, though investors from a year ago are still down 64%

TG Therapeutics (TGTX) Reports Q2 Loss, Tops Revenue Estimates

S&P 500
4,274.04
-31.16(-0.72%)

Dow 30
33,980.32
-171.69(-0.50%)

Nasdaq
12,938.12
-164.43(-1.25%)

Russell 2000
1,987.31
-33.22(-1.64%)

Crude Oil
87.29
-0.82(-0.93%)

Gold
1,776.30
-0.40(-0.02%)